Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric Cancer
The goal of this clinical trial is to explore the efficacy and safety in patients with gastric adenocarcinoma or adenocarcinoma of esophagogastric junction. The main questions it aims to answer are:

* Does this therapy have a promising efficacy?
* Does this therapy have a manageable toxicity? Participants will receive fruquintinib plus sintilimab as first-line therapy for gastric cancer.
Stomach Neoplasms
DRUG: Fruquintinib|DRUG: Sintilimab
Objective response rate (ORR), The proportion of patients with complete response or partial response, using RECIST v 1.1., 12 months
Progression-Free Survival (PFS), Time from enrollment to the first documented disease progression or death due to any cause, whichever occurs first. Responses are according to the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by investigator, 12 months|Overall survival (OS), Time from randomization to death from any cause., 12 months|Disease Control Rate (DCR), The proportion of patients with complete response, partial response or stable disease, using RECIST v 1.1., 12 months|Adverse Events, Adverse event assessed according to CTCAE v5.0., 12 months
The goal of this clinical trial is to explore the efficacy and safety in patients with gastric adenocarcinoma or adenocarcinoma of esophagogastric junction. The main questions it aims to answer are:

* Does this therapy have a promising efficacy?
* Does this therapy have a manageable toxicity? Participants will receive fruquintinib plus sintilimab as first-line therapy for gastric cancer.